Biomarin Pharmaceutical

Barclays analyst Gena Wang assigns a Buy rating to Vir Biotechnology with a $26.00 price target. Wang, a 4-star analyst with a 41.25% success rate, also covers BioMarin Pharmaceutical, Avidity Biosciences, and Alnylam Pharma. Vir Biotechnology received a Buy rating from H.C. Wainwright’s Patrick Trucchio and a Hold rating from Morgan Stanley. The company’s market cap is $1.1B with a P/E ratio of -2.04, and insider sentiment is negative due to increased insider selling.

Infigratinib, an oral FGFR1-3 inhibitor, showed safety and efficacy in a phase II study among children with achondroplasia, with increased annualized height velocity and sustained height z score improvements.

TD Cowen's Phil Nadeau maintains Buy rating on Vir Biotechnology (VIR), with shares closing at $7.49. Nadeau, with a 5.5% average return and 44.49% success rate, covers Biogen, BioMarin, and Annexon. Analyst consensus rates VIR as Moderate Buy with a $36.00 target. Vir reported $3.08M revenue and $138.38M GAAP net loss for Q2, compared to $3.8M revenue and $194.78M loss in the prior year. Vir Biotechnology focuses on treating infectious diseases using antibody, T cell, innate immunity, and siRNA technologies.

AbbVie, a pharmaceutical firm with strong immunology and oncology portfolios, is compared against key competitors in the Biotechnology industry. Analysis reveals AbbVie's PE ratio is low, suggesting potential undervaluation, while its high PB ratio indicates overvaluation based on book value. A low PS ratio implies undervaluation based on sales. AbbVie's high ROE, EBITDA, and gross profit highlight strong profitability and operational efficiency, but low revenue growth indicates challenges in market expansion.

Global exosome market to grow at ~20% CAGR by 2030, driven by chronic disease incidence, diagnostic improvements, and personalized medicine interest. North America leads, with key players like Danaher and Thermo Fisher Scientific. Notable developments include Aruna Bio's US patent for neural exosomes and EXO Biologics' EUR 16 million Series A funding.

DelveInsight's 'Hemophilia A Pipeline Insight 2024' covers global Hemophilia A therapies, highlighting over 40+ pipeline therapies, key companies like Spark Therapeutics, Pfizer, and Sanofi, and recent FDA approvals for Roctavian and ALTUVIIIO. The report assesses the therapeutic landscape, including product types, stages, routes of administration, and molecule types.

DelveInsight's 'Hemophilia A Pipeline Insight 2024' covers global Hemophilia A therapies, highlighting over 40+ pipeline therapies, key companies like Spark Therapeutics, Pfizer, and Novo Nordisk, and recent FDA approvals for Roctavian and ALTUVIIIO.

FDA approves Pfizer's Hympavzi, a new weekly injection for hemophilia A and B, which reduces TFPI activity to prevent bleeding. This expands Pfizer's hemophilia treatments, offering flexibility and lower bleeding rates compared to traditional factor replacement. Common side effects include injection site reactions, headache, and itching.

Pfizer's Hympavzi, a once-weekly injection for hemophilia A or B, received FDA approval. The drug, administered via auto-injector, aims to reduce bleeding episodes and treatment burden. Sales are projected to reach $300 million by 2030.